推荐产品
等級
pharmaceutical primary standard
API 家族
flutrimazole
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
InChI
1S/C22H16F2N2/c23-19-12-10-18(11-13-19)22(26-15-14-25-16-26,17-6-2-1-3-7-17)20-8-4-5-9-21(20)24/h1-16H
InChI 密鑰
QHMWCHQXCUNUAK-UHFFFAOYSA-N
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Flutrimazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
In vitro and in vivo studies with flutrimazole, a new imidazole derivative with antifungal activity.
J García Rafanell et al.
Arzneimittel-Forschung, 42(6), 836-840 (1992-06-01)
1-[(2-Fluorophenyl)(4-fluorophenyl)phenylmethyl]-1H-imidazole (flutrimazole, UR-4056, CAS 119006-77-8) is a new topical imidazole antifungal agent which displays potent broad-spectrum in vitro activity against dermatophytes, filamentous fungi and yeasts, saprophytic and pathogenic to animals and humans (MIC = 0.025-5.0 micrograms/ml). In most of these
del Palacio et al.
Mycoses, 38(9-10), 395-403 (1995-09-01)
In a double-blind, randomized study the efficacy and tolerance of flutrimazole 1% solution were compared with bifonazole 1% solution, applied once daily for 4 weeks, in 40 patients with culturally proven dermatophytosis or cutaneous candidosis. Forty patients with mycologically proven
A Alomar et al.
Dermatology (Basel, Switzerland), 190(4), 295-300 (1995-01-01)
Flutrimazole is a new imidazole derivate. Its antifungal activity has been demonstrated in in vivo and in vitro studies to be comparable to that of clotrimazole and higher than bifonazole. To compare the efficacy and tolerability of flutrimazole cream 1%
Synthesis and antifungal activity of a series of difluorotritylimidazoles.
J Bartrolí et al.
Arzneimittel-Forschung, 42(6), 832-835 (1992-06-01)
A del Palacio et al.
Mycoses, 43(9-10), 355-365 (2000-12-06)
A double-blind randomized comparative phase II study of flutrimazole site-release vaginal cream (1, 2 and 4%) with placebo site-release vaginal cream was undertaken in patients with acute vulvovaginal candidosis. Vaginitis was demonstrated by both positive findings on microscopic examination of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门